Entera Bio Ltd.

NASDAQ:ENTX

Biotechnology

Healthcare
$3.26 +0.00%

+$0.00 today

Market cap
$567.69M
Beta
1.49
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.91High $3.22

Volume 0.49M

Average 0.16M

ENTX Interest Expense

Cost of servicing the company's debt during the period.

Entera Bio Ltd.NASDAQ: ENTX

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0-100.0% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How ENTX compares with its peers on the latest reported figures

  • ENTX's LTM Mar 2026 interest expense of $0 is the 5th highest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -100.0% is the 5th highest of 6, against a peer median of -43.4%.
ENTX Competitors Peer median
Interest Expense for ENTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$57.17M -43.4%-3.7%46.2%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$4.27M +4.4%——
IRDOpus Genetics, Inc.LTM Mar 2026$2.15M +56.9%+446.1%18.0%
HURATuHURA Biosciences, Inc.LTM Mar 2026$653.26K -83.2%——
ENTXEntera Bio Ltd.LTM Mar 2026$0 -100.0%——
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$0 ———
ANIXAnixa Biosciences, Inc.LTM Apr 2026$0 ———
SEERSeer, Inc.LTM Mar 2026$0 ——0.0%
SPROSpero Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
Peer median (excluding ENTX) $0-43.4%+221.2%0.0%

Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue571K134K0181K42K
Cost of Revenue373K165K56K172K42K
Gross Profit198K(31K)(56K)9K0
Gross Margin34.7%-23.1%—5.0%0.0%
Research & Development6.77M5.78M4.45M4.5M6M
Selling, General & Admin5.69M7.25M4.43M5.1M5.53M
Operating Expenses12.42M13.04M8.88M9.59M11.53M
Depreciation & Amortization53K64K56K46K30K
EBITDA(12.16M)(12.87M)(8.8M)(9.48M)(11.41M)
EBITDA Margin-2130.3%-9604.5%—-5238.1%-27164.3%
Operating Income(12.22M)(13.07M)(8.94M)(9.59M)(11.53M)
Operating Margin-2139.6%-9752.2%—-5295.6%-27450.0%
Interest Income083K31K58K0
Interest Expense29K0000
Other Income / Expenses(29K)134K80K58K90K
Income Before Tax(12.25M)(12.93M)(8.86M)(9.53M)(11.44M)
Pre-Tax Margin-2144.7%-9652.2%—-5263.5%-27235.7%
Income Tax Expense(59K)137K29K14K0
Net Income(12.19M)(13.07M)(8.89M)(9.54M)(11.44M)
Net Margin-2134.3%-9754.5%—-5271.3%-27235.7%
EPS (Basic)(0.47)(0.45)(0.31)(0.25)(0.25)
EPS (Diluted)(0.47)(0.45)(0.31)(0.25)(0.25)
Weighted Avg Shares26.13M28.81M29.01M37.65M46.19M
Weighted Avg Shares (Diluted)26.13M28.81M29.01M37.65M46.19M

Entera Bio Ltd.

NASDAQ:ENTX

Intrinsic Alpha fair value

Locked

Current Price

$3.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.